Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...

Marks the Third Year Since the Launch of the First US Biosimilar Market Report INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Co., Ltd. today released its First Quarter 2025 Biosimilar ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

While most of its current revenue comes from the contract manufacturing business, Samsung Biologics aims to increase its exposure in the contract development organization business, which provides a ...

Samsung launches online marketplace to boost domestic economy for Lunar New Year Samsung aims to enhance holiday shopping ...

In a judgment of 23 December 2024, the Dutch-speaking Enterprise Court of Brussels followed the reasoning of a Dutch court earlier in 2024, ...